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ABSTRACT
Introduction: In treatment of prosthetic
vascular graft infection (PVGI), appropriate
antimicrobial treatment is crucial for
controlling the septic process and preventing
re-infection of the new graft. Glycopeptides are
the mainstay of treatment for device-related
infections by methicillin-resistant
Staphylococcus aureus strains, but with some
limitations, especially concerning vancomycin-
intermediate and glycopeptide-intermediate S.
aureus. We report our experience using a high
dose of daptomycin (DAP) for treatment of
PVGI.
Methods: We reviewed medical reports of 26
patients treated with high doses of DAP
([8 mg/kg) and beta-lactams/aminosides for
PVGI, defined as positive bacterial culture of
intraoperative specimens or blood samples and/
or clinical, biological, and radiological signs of
infection. Clinical success was defined by
resolution of all clinical signs at the end of
follow-up, without the need for additional
antibiotic therapy, and/or negative culture in
case of new surgery.
Results: Cultures of intraoperative samples
were positive in 21 patients (80.8%). Blood
and intraoperative cultures were concomitantly
positive in 10 patients. The main
microorganism identified in microbiological
samples was S. aureus (n = 18). Surgery was
performed in 23 patients (88.4%). The mean
duration of the DAP regimen was
12.3 ± 11.9 days. DAP was discontinued in 26
patients [need to switch to microbiological
results (n = 19), bacterial pneumonia (n = 2),
and increased creatine phosphokinase levels
(n = 4)]. One patient had myalgia, while 9
received concomitant statins.
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Conclusion: High-dose DAP therapy shows a
satisfactory toxicity profile even in severely ill
patients with multiple comorbidities, and may
favorably compete with vancomycin, especially
concerning the risk of induced nephrotoxicity.
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INTRODUCTION
Prosthetic vascular graft infection (PVGI) is a
severe complication of vascular surgery that
carries high morbidity and mortality rates [1–3].
A surgical approach, combining excision of the
graft, complete debridement of devitalized and
infected tissues and maintenance of vascular
flow to the distal bed, is consistently required,
although some patients are not fit for operative
intervention [1, 4]. The choice of antimicrobial
agents as empirical or definitive therapy and the
duration of treatment remain unclear. One
major challenge lies in the rapid development
of bacterial biofilms on intravascular leads that
are relatively impermeable to antimicrobial
treatment [5, 6]. Thus, the appropriate
antimicrobial treatment is crucial for
controlling the septic process and the risk of
graft rupture. Since most PVGIs are due to
staphylococci or, to a lesser extent, to Gram-
negative bacilli, daptomycin (DAP) could be an
option in association with beta-lactams.
DAP is a cyclic lipopeptide with rapid
concentration-dependent bacterial activity
against Gram-positive pathogens. DAP has
been approved in Europe and USA for
treatment of complicated skin and soft tissue
infections, bacteremia and right-sided infective
endocarditis caused by Staphylococcus spp. at 4
and 6 mg/kg once daily, respectively [7, 8]. At
6 mg/kg/day, DAP does not perform better than
standard therapy for endocarditis [7]. Despite its
recent arrival on the market of anti-infective
agents, DAP-resistant mutants have already
been reported [9–12]. To prevent the
occurrence of resistant mutants (especially in
the presence of foreign bodies) [13–16] and to
limit the increase in staphylococcal minimum
inhibitory concentration (MIC) [17, 18], some
authors [19, 20] suggest increasing the daily
dose of DAP. Clinical experience with a dose
[6 mg/kg is limited, but data reported to date
suggest that DAP is safe and well-tolerated
[20–22].
In this report, we present our center’s
experience with high-dose DAP for empirical
treatment of PVGI during the very crucial post-
operative period, and as treatment adapted to
microbiological results.
METHODS
The present study was retrospectively
conducted from January 2008 to December
2010 and included all patients treated with
DAP for PVGI at our regional referral centers for
these infections (University Hospital of Lille,
Lille, France and Dron Hospital, Tourcoing,
France). The objective of this study was to
evaluate the safety of DAP at daily dosages
[8 mg/kg in patients with PVGI. This study was
approved by the institutional review boards of
Dron Hospital and the University Hospital of
Lille. All patients included in this study were
informed and gave their consent. As in our
previous studies [3], as there is no standard
definition for diagnosis of definite or suspected
PVGI, we used criteria proposed by FitzGerald
et al. [1]. A patient was considered as suffering
from clear-cut PVGI if at least two of the
following three criteria were present:
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(a) positive bacterial culture of intraoperative
specimens or blood samples (for potentially
contaminant bacteria, such as coagulase-
negative staphylococci, Propionibacterium acnes,
or corynebacteria, at least two intraoperative
specimens or blood samples or at least one
intraoperative specimen and one blood culture
were required); (b) clinical signs of infection in
the area of the prosthesis; (c) biological or other
radiological signs of infection (perigraft air or
fluid persisting for more than 8 weeks post-
operatively; abscess). Each case of definite
infection was classified as early-onset infection
when occurring within 4 months after surgery
or as late-onset infection when occurring more
than 4 months after surgery. PVGI or stent
infection was suspected when bacteremia
involving a site other than the surgical site
occurred in the early post-operative period
(within 4 weeks of graft or stent implantation)
[23, 24]. PVGI was documented only by
intraoperative or blood samples. Superficial
samples were excluded. Multiple intraoperative
samples were cultured on blood agar plates with
standard aerobic and anaerobic methods.
Antibiotic susceptibility patterns were
interpreted in accordance with
recommendations of the ‘‘Comite´ de
l’Antibiogramme de la Socie´te´ Franc¸aise de
Microbiologie’’ [25]. DAP was started in
combination with broad-spectrum beta-
lactams (e.g., piperacilline tazobactam) with or
without aminoglycosides as first-line empiric
antibiotic treatment in patients who had
suspected or definite PVGI immediately after
intraoperative samples were taken, or as second-
line treatment in those who experienced
adverse effects with a prior antibiotic regimen.
To treat infection and to maintain or re-
establish vascular flow to the distal bed,
optimal surgical treatment included complete
debridement of devitalized and infected tissues
around the prosthesis, total graft excision, and
in situ reconstruction with a new prosthesis,
autogenous vein, or arterial allograft/
homograft. Debridement without graft
excision was proposed to patients with very
early PVGI or to patients with severe
comorbidities. Finally, when revascularization
was not possible, amputation was proposed to
the patient. Patients were evaluated at the end
of DAP therapy and at the end of culture-guided
therapy; in the case of prosthetic or homograft,
they were followed up for 1 year after the end of
treatment and, in case of venous graft, for
3 months after the end of treatment. Clinical
success was defined by resolution of all clinical
signs at the end of follow-up, with no need for
additional antibiotic therapy, and/or negative
culture in case of new surgery. Failure was
defined as any other outcome. The safety of
DAP was assessed on renal function and creatine
phosphokinase (CPK) blood levels during
treatment. For statistical analysis, numerical
data are presented as mean (SD) or median
and range. Categorical data are presented as
number and percentage. Statistical analysis was
performed using Stata (version 9; StataCorp
LP, College Station, TX, USA).
RESULTS
Among the 128 patients with suspected or
definite PVGI from January 2008 to December
2010 at our two referral centers, 30 (23.4%) were
treated with DAP doses [8 mg/kg per day in
association with broad-spectrum beta-lactams
for PVGI and gave their written consent for
treatment. Four patients were excluded because
of missing data or suspected PVGIon follow-up.
Finally, 26 patients were included in our study.
Patient demographic and clinical characteristics
are listed in Table 1. Most of patients had
intracavitary PVGI (69.2%). Half of the patients
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had early post-operative PVGI. Radiological
signs included false aneurysm (n = 1),
disruption of PVGI (n = 3), thrombosis (n = 2),
and periprosthetic collection (n = 24).
Microbiological documentation was obtained
in 21 patients (80.1%) despite previous
antibiotic administration (n = 16) within the
2 days prior to DAP treatment: penicillin
(n = 12), carbapenems (n = 1), glycopeptides
(n = 6), fluoroquinolones (n = 4), glycylcyclines
(n = 1), aminoglycosides (n = 2), or
miscellaneous agents (n = 3). Cultures of
Table 1 Characteristics of patients of the study
Patients (n 5 26) n (%)a
Gender: male 21 (80.8)
Mean age (years ± SD) 62 ± 10.7
Comorbidities




Arterial coronary disease 14 (53.9)
Severe renal chronic failure
(\30 mL/min)
1 (3.9)
Moderate renal chronic failure
(30–60 mL/min)
7 (26.9)
Clinical presentation at entry
Intracavitary PVGI 18 (69.2)
Extracavitary PVGI 8 (30.8)
Early PVGI 14 (53.9)
Late PVGI 12 (46.2)
Fever 21 (80.8)
Local erythema 15 (57.7)
Productive ﬁstula 14 (53.9)
Abdominal pain 8 (30.8)
Septic shock 6 (23.1)
Weight (mean ± SD; kg) 76.2 ± 11.7
Biological data at entry
Creatinine clearance (mean ± SD;
mL/min)
82.9 ± 33
WBC (mean ± SD; /mm3) 12,445 ± 5,389
C-reactive protein (mean ± SD; mg/L) 102 ± 96
Microbiological data
Positive blood sample 9 (34.6)
Positive intraoperative sample 21 (80.8)
No bacterial growth 5 (19.2)
Polymicrobial sample 5 (19.2)
Table 1 continued




Streptococcus sp. 5 (19.2)
Enterococcus faecalis 2 (19.2)
Gram-negative bacilli 8 (30.8)
Fungi 1 (3.9)
Initial treatment option of PGVI
PVGI removed 17 (65.4)
Debridement in situ without prosthetic
removal
6 (23.1)
Medical treatment without surgery 3 (11.5)
Outcome
New surgery 12 (46.2)
Previous or concomitant treatment
Previous antibiotic treatment 16 (61.5)
Concomitant treatment with statins 9 (34.6)
CNS coagulase-negative staphylococci, COPD chronic
obstructive pulmonary disease, MRSA methicillin-
resistant Staphylococcus aureus, MSSA methicillin-sensitive
Staphylococcus aureus, PVGI prosthetic vascular graft
infection, WBC white blood cells
a Vaules are presented as n (%) unless otherwise stated
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intraoperative samples were positive in 21
patients (80.1%). Blood and intraoperative
cultures were concomitantly positive in 10
patients. The main microorganism identified in
microbiological samples was Staphylococcus sp.
(n = 18), including 11 methicillin-sensitive S.
aureus (MSSA), 5 methicillin-resistant S. aureus
strains (MRSA), and 2 methicillin-sensitive
coagulase-negative staphylococci. All MRSA
strains were susceptible to glycopeptides. No
MIC for DAP was performed. The initial
treatment options were: graft excision and
replacement of the infected prosthesis by an
in situ allo/homograft (n = 10), autologous vein
(n = 1), or new prosthesis (n = 6); debridement
without removed prosthesis (n = 6) and medical
treatment without surgery (n = 3). All patients
were treated with DAP as empirical treatment
after intraoperative samples and/or blood
cultures were taken. The mean DAP daily
dosage was 729 ± 151 mg (9.5 mg/kg), except
for 2 patients under hemodialysis who received
850 mg/48 h. Mean duration of the DAP
regimen was 12.3 ± 11.9 days. The agents most
frequently associated with DAP were piperacillin
tazobactam (n = 16), imipenem (n = 4),
caspofungin (n = 5), or other (n = 2). The
empirical antibiotic was adequate in 100% of
patients included in the study. Fourteen patients
(53.8%) were admitted to the intensive care
unit. The main complications were septic shock
(n = 6), acute renal failure (n = 5) including
those requiring hemodialysis (n = 2), graft
disruption (n = 4), and pneumonia (n = 2). A
second surgical procedure was necessary for 10
patients during the same hospital stay, with a
mean interval of 5.6 days, due to persistent
infection in most cases. In 6 patients, vascular
graft was removed and replaced by allo/
homograft. For the others, debridement was
performed. New microorganisms were identified
in 3 patients (Enterococcus sp. n = 1; Enterobacter
sp. n = 2, E. coli n = 2, Candida sp. n = 1). During
hospitalization, five patients died of a cause
directly related to PVGI. Deaths were not
directly related to the DAP regimen, but rather
to the general condition of patients and
disruption of the graft. For the 21 survivors,
mean follow-up was 394 ± 265 days
(123–1,376). No relapse was observed, but two
patients died of pulmonary cancer during
follow-up. No dosage of DAP was performed.
No neutropenia or eosinophilic pneumonia was
observed. Mean CPK blood levels at baseline and
at the end of DAP therapy were, respectively,
38 ± 23 UI/L and 287 ± 221 UI/L, whereas
creatinine blood levels were quite similar
(13.1 ± 1.2 vs. 10.8 ± 5.5 mg/L) (Fig. 1). One of
these patients had myalgia without renal
impairment. Among the 9 patients who
received concomitant statins, 3 of them had
increased CPK blood levels. The reasons for
discontinuing DAP was the use of antibiotic
agents with narrow spectrum, guided by the
microbiological results (n = 19), bacterial
pneumonia (n = 2), or DAP-related adverse
effects (i.e., myalgia [n = 1], increased CPK
levels [n = 4]). No dosage of DAP was performed.
DISCUSSION
Results of the present study suggest that DAP
[8 mg/kg/day, when used to treat a variety of
PVGI due to Gram-positive cocci in severely ill
patients with multiple comorbidities, shows a
favorable safety profile, in agreement with
previous studies, as well as a satisfactory
clinical success rate [19–22].
Most of our patients were over 65 and
severely ill, with high risk of mortality, sepsis,
renal disorders due to the sepsis, vasopressor
drug use, occlusive arterial disease, and
‘‘clampage of the aorta’’. Despite these
recognized risk factors in renal failure,
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nephrotoxicity was not detected in our
population of patients, in contrast to results of
vancomycin therapy reported in recent clinical
studies [26, 27].
Several patients in our study experienced
increased CPK blood levels, some with
concomitant statins. With or without statins,
clinical and biological abnormalities
disappeared within a week. In pre-clinical
studies [28, 29], DAP has been linked to fully
reversible skeletal muscle toxicity, with no
effect on smooth or cardiac muscle. A
significant rise in the CPK level was noted,
from 2.5% to 8.3%. However, in the present
study, it was not clear whether the rise in CPK
levels was due to the higher dosage regimen and
concomitant use of statins, or whether it was
the effect of peri-operative status (i.e., time of
clampage of the aorta, septic shock,
concomitant use of vasopressive agents) [30,
31]. No eosinophilic pneumonia was observed
in our study.
Unlike vancomycin, DAP has shown similar
efficacy against both MRSA and MSSA, making
it an attractive option for empirical therapy of
suspected severe infections due to Gram-
positive cocci [5–7, 13–17, 19–22].
DAP exhibits bactericidal activity against
both methicillin-susceptible and -resistant
staphylococci, including those with MIC
[1 mg/L, and, in vitro, it kills bacteria faster
than comparable drugs [7, 8]. Experimental
Fig. 1 Creatine phosphokinase (CPK) and creatinine level rate during daptomycin (DAP) regimen
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studies [5, 6, 13–17] suggest that it may prevent
bacterial adherence, penetrate into the biofilm
and prevent further biofilm formation.
In the present study, [80% of PVGI were
microbiologically documented. Once the results
of bacterial culture were available, empiric
antimicrobial therapy was adapted, using, if
possible, a step-down strategy. All patients
underwent adaptation of antimicrobial drugs
during the post-operative period, which we feel
is crucial to prevent recolonization of the newly
implanted graft. During their hospital stay, five
patients died; deaths were related to graft
disruption, possibly explained by problems in
anastomosis between the graft and the infected
aorta tissues. However, in our study, the efficacy
of DAP in PVGI cannot be determined. Indeed,
the overwhelming majority of patients received
beta-lactam antibiotics with or without
aminoglycosides in addition to DAP. A
secondary surgery procedure was required for
10 patients with persistent infection. For these
last patients, we considered that the first surgery
was not considered to be optimal. Randomized
studies would be more appropriate to study the
efficacy of DAP in patients treated for PVGI. The
main limitation would be the homogenous
patients treated with homogenous surgical and
medical procedure.
CONCLUSION
In conclusion, results of the present study
suggest that high-dose DAP (i.e., [8 mg/kg) for
patients with PVGI due to Gram-positive cocci
represents a potentially interesting option for
treatment of such infections. High-dose DAP
therapy has a satisfactory toxicity profile even
in severely ill patients with multiple
comorbidities, and might favorably compete
with vancomycin, especially in terms of risk of
induced nephrotoxicity. However, monitoring
of CPK levels is recommended in these patients,
especially if they are concomitantly treated with
statins.
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